Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).
dc.contributor.author | Matasar, Matthew | |
dc.contributor.author | Turgut, Burhan | |
dc.contributor.author | Tessoulin, Benoit | |
dc.contributor.author | Guidez, Stephanie | |
dc.contributor.author | Altuntas, Fevzi | |
dc.contributor.author | Iqbal, Nazia | |
dc.contributor.author | Namuduri, Manjusha | |
dc.date.accessioned | 2024-10-29T17:58:16Z | |
dc.date.available | 2024-10-29T17:58:16Z | |
dc.date.issued | 2024 | |
dc.department | Tekirdağ Namık Kemal Üniversitesi | |
dc.description | Special Clinical Science Symposia -- MAY 29-29, 2024 -- ELECTR NETWORK | |
dc.description.abstract | [Abstract Not Available] | |
dc.description.sponsorship | Regeneron Pharmaceuticals, Inc. | |
dc.description.sponsorship | Regeneron Pharmaceuticals, Inc. | |
dc.identifier.issn | 0732-183X | |
dc.identifier.issn | 1527-7755 | |
dc.identifier.issue | 16 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.11776/14165 | |
dc.identifier.volume | 42 | |
dc.identifier.wos | WOS:001275557406337 | |
dc.identifier.wosquality | N/A | |
dc.indekslendigikaynak | Web of Science | |
dc.language.iso | en | |
dc.publisher | Lippincott Williams & Wilkins | |
dc.relation.ispartof | Journal of Clinical Oncology | |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.title | Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3). | |
dc.type | Conference Object |